厄洛替尼联合贝伐珠单抗治疗 EGFR 突变型非小细胞肺癌有效。

Erlotinib plus bevacizumab is effective in EGFR-mutant NSCLC.

出版信息

Cancer Discov. 2014 Nov;4(11):OF18. doi: 10.1158/2159-8290.CD-RW2014-194. Epub 2014 Sep 11.

DOI:10.1158/2159-8290.CD-RW2014-194

PMID:25367959

Abstract

The combination of erlotinib and bevacizumab prolongs PFS in patients with EGFR-mutant NSCLC.

摘要

厄洛替尼联合贝伐珠单抗延长 EGFR 突变型 NSCLC 患者的无进展生存期。

相似文献

Erlotinib plus bevacizumab is effective in EGFR-mutant NSCLC.

Cancer Discov. 2014 Nov;4(11):OF18. doi: 10.1158/2159-8290.CD-RW2014-194. Epub 2014 Sep 11.

EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.

Cancer Chemother Pharmacol. 2015 Oct;76(4):835-41. doi: 10.1007/s00280-015-2867-8. Epub 2015 Sep 8.

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.

Lancet Oncol. 2014 Oct;15(11):1236-44. doi: 10.1016/S1470-2045(14)70381-X. Epub 2014 Aug 27.

Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.

J Clin Oncol. 2011 Jun 20;29(18):2582-9. doi: 10.1200/JCO.2010.30.7678. Epub 2011 May 16.

Overcoming resistance to first generation EGFR TKIs with cetuximab in combination with chemotherapy in an EGFR mutated advanced stage NSCLC patient.

Lung Cancer. 2014 Mar;83(3):408-10. doi: 10.1016/j.lungcan.2013.12.007. Epub 2013 Dec 25.

Salvage with erlotinib plus bevacizumab: not in NSCLC.

Lancet. 2011 May 28;377(9780):1810-2. doi: 10.1016/S0140-6736(11)60740-X.

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.

Lung Cancer. 2014 May;84(2):161-7. doi: 10.1016/j.lungcan.2014.02.011. Epub 2014 Mar 2.

Angiogenesis inhibition in the treatment of lung cancer.

Clin Adv Hematol Oncol. 2006 Nov;4(11 Suppl 23):1-10; quiz 11-2.

A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.

Lung Cancer. 2013 Nov;82(2):276-81. doi: 10.1016/j.lungcan.2013.08.002. Epub 2013 Aug 13.

ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.

J Clin Oncol. 2013 Nov 1;31(31):3926-34. doi: 10.1200/JCO.2012.47.3983. Epub 2013 Oct 7.

引用本文的文献

Exosomal miR-141 promotes tumor angiogenesis via KLF12 in small cell lung cancer.

J Exp Clin Cancer Res. 2020 Sep 21;39(1):193. doi: 10.1186/s13046-020-01680-1.

Efficacy and safety of erlotinib combined with bevacizumab in the treatment of non-small cell lung cancer: A systematic review and meta-analysis.

Medicine (Baltimore). 2020 Jan;99(3):e18771. doi: 10.1097/MD.0000000000018771.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

厄洛替尼联合贝伐珠单抗治疗 EGFR 突变型非小细胞肺癌有效。

Erlotinib plus bevacizumab is effective in EGFR-mutant NSCLC.

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献